Showing results (251-260 of 324) with videos related to

Sort By:
Pageof 33
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.
The Lancet. Oncology|May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyByoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.
Cancer Science|July 5, 2018
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutationsHaruyasu Murakami, Hiroshi Nokihara, Hidetoshi Hayashi, et al.
The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.
The Lancet. Oncology|March 29, 2012
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialJames Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, et al.
Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.
Lung Cancer (Amsterdam, Netherlands)|February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisHidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.
Clinical Lung Cancer|November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.
Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
Pageof 33